Molecular Therapy · 2002 · 62 citations · 33 references
Life SciencesBiochemistryMolecular GeneticsGene DeliveryGene TherapyVirologyViral InfectionsViral ReleaseFetal Skeletal GrowthGene-targeted TherapyGlycosaminoglycan AccumulationGlycosaminoglycan BreakdownGlycosaminoglycan MetabolismInducible Gene TherapyMucopolysaccharidosis-associated Skeletal DiseaseStunted Growth
Previous treatment of mucopolysaccharidosis type VII mice (Sly syndrome) with AAV vectors has resulted in increased levels of β-glucuronidase (GUS) enzyme in some tissues with reduction of glycosaminoglycan storage granules and improved health. By adding coding sequences for secretion (Igκ) and uptake (HIV-1 TAT) signals to the GUS gene delivered by AAV, and treating mice both intrathecally and intravenously as newborns, we have increased the GUS enzyme levels in more tissues and have improved the health of the mice so much that they are able to breed. The levels of GUS in the serum were above normal in some mice, which caused reduction of storage in the spleen, a nontransduced tissue. The heart and aorta showed therapeutic levels of GUS enzyme. AAV GUS DNA was found in brain and liver, which showed no storage. Phenotypically the treated mice were more active and showed less stunted skeletal growth. The pups born to these mice were not affected by the gene therapy, as shown by mutant levels of GUS enzyme in their tissues and the absence of AAV GUS DNA. However, they were resistant to intravenous treatment with AAV GUS due to the mother's antibodies, but not to intrathecal treatment. Previous treatment of mucopolysaccharidosis type VII mice (Sly syndrome) with AAV vectors has resulted in increased levels of β-glucuronidase (GUS) enzyme in some tissues with reduction of glycosaminoglycan storage granules and improved health. By adding coding sequences for secretion (Igκ) and uptake (HIV-1 TAT) signals to the GUS gene delivered by AAV, and treating mice both intrathecally and intravenously as newborns, we have increased the GUS enzyme levels in more tissues and have improved the health of the mice so much that they are able to breed. The levels of GUS in the serum were above normal in some mice, which caused reduction of storage in the spleen, a nontransduced tissue. The heart and aorta showed therapeutic levels of GUS enzyme. AAV GUS DNA was found in brain and liver, which showed no storage. Phenotypically the treated mice were more active and showed less stunted skeletal growth. The pups born to these mice were not affected by the gene therapy, as shown by mutant levels of GUS enzyme in their tissues and the absence of AAV GUS DNA. However, they were resistant to intravenous treatment with AAV GUS due to the mother's antibodies, but not to intrathecal treatment.
33
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Steven R. Schwarze, Alan L. Ho, Adamina Vocero-Akbani et al. · Science · 1999 · 2.4K citations
Annual Review of Biochemistry · 1991 · 902 citations
Adeno-associated virus vectors can be efficiently produced without helper virus
Takashi Matsushita, SS Elliger, CA Elliger et al. · Gene Therapy · 1998 · 495 citations